Pflugers Arch 442:28696 Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T, Takahashi S, Bannai S (2005) Redox imbalance in cystine/glutamate transporter-deficient mice
The American Diabetes Association (ADA) now recommends GLP-1 agonists for overweight individuals with diabetes, particularly those who experience frequent hypoglycemia with insulin or sulfonylureas
It depends on dose
Processed foods often lack fiber and contain additives that can worsen constipation
In silico assessment of immunogenic potential allows for risk-based selection of best candidate peptides in further confirmatory in vitro, ex vivo, and in vivo assays, thereby reducing the overall cost of immunogenicity evaluation
Sun Pharma is developing utreglutide, a longacting GLP1 designed to offer metabolic benefits with potentially lower cost and broader accessibility, positioning the company as a future valuedriven challenger to the highpriced injectable and oral franchises of Novo and Lilly
